| Literature DB >> 33414781 |
Ingrid Kazue Mizuno Watanabe1,2, Magaiver Andrade-Silva2, Orestes Foresto-Neto1, Raphael José Ferreira Felizardo1, Marco Aurélio Costa Matheus2, Reinaldo Correa Silva1, Marcos Antônio Cenedeze2, Tâmisa Seeko Bandeira Honda1, Luiz Augusto Buoro Perandini1, Rildo Aparecido Volpini3, Alvaro Pacheco-Silva2,4, Niels Olsen Saraiva Câmara1,2.
Abstract
Increasing evidence shows the essential participation of gut microbiota in human health and diseases by shaping local and systemic immunity. Despite an accumulating body of studies showing that chronic kidney disease (CKD) is closely associated with disturbances in the composition of gut microbiota, it remains unclear the importance of gut microbiota in the onset and development of CKD. For the purpose of untangling the role of gut microbiota in CKD, gut microbiota was depleted with a pool of broad-spectrum antibiotics in mice submitted to unilateral ureteral obstruction (UUO). Depletion of gut microbiota significantly decreased levels of proinflammatory cytokines and fibrosis markers, attenuating renal injury. Additionally, to study whether the pathogenic role of gut microbiota is dependent of microbial-host crosstalk, we generated mice lacking Myd88 (myeloid differentiation primary response gene 8) expression in intestinal epithelial cells (IECs) and performed UUO. The absence of Myd88 in IECs prevented a bacterial burden in mesenteric lymph nodes as observed in WT mice after UUO and led to lower expression of proinflammatory cytokines and chemokines, reducing deposition of type I collagen and, ultimately, attenuating renal damage. Therefore, our results suggest that the presence of gut microbiota is crucial for the development of CKD and may be dependent of Myd88 signaling in IECs, which appears to be essential to maturation of immune cells intimately involved in aggravation of inflammatory scenarios.Entities:
Keywords: Myd88; chronic kidney disease; fibrosis; gut microbiota; inflammation
Year: 2020 PMID: 33414781 PMCID: PMC7783078 DOI: 10.3389/fimmu.2020.578623
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561